Loading
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (4 ops.)
Latest filing published 08 Sept 2026 for Contineum Therapeutics, Inc., €2,170.
Filing timeline
BuySaleCarmine N. Stengone
Insider track record
Disclosed buys
1
Disclosed sells
4
Signal history
Closed purchases
Market purchases
1
Not enough history yet: 1 closed purchase, at least 2 are needed.
Purchases by company
Since each purchase
- -28.7%Entry US$3.66 · Close at T+365 US$2.61
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Carmine N. Stengone: trading record in brief
This profile gathers the share dealings of Carmine N. Stengone across 2 companies, led by Contineum Therapeutics, Inc. and Kiora Pharmaceuticals Inc. We count 12 filings; the first trade dates from 11 September 2024 and the latest from 8 September 2026.
Market trades split into 1 purchase (€4,178) and 4 sales (€245k). On balance, insiders were net sellers of €241k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 7 option exercises. Since January 2026: no purchases and 4 sales on the market.
The newest entry dates from 8 September 2026: an option exercise of €2,170, in Contineum Therapeutics, Inc. The last purchase on record was published on 12 September 2024, which is 772 days ago. Typically, a trade is published a median of 1 day after it takes place. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Carmine N. Stengone
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations12 total
2,500 shares@ US$1.010.0005% mcap1.9% of flowClass A Common StockSEC:0001628280-26-060962:0
2,500 shares@ US$16.45660.0085% mcap30.3% of flowClass A Common StockSEC:0001628280-26-060962:1
2,500 shares@ US$1.010.0005% mcap1.9% of flowClass A Common StockSEC:0001628280-26-052031:0
2,500 shares@ US$16.01160.0084% mcap29.7% of flowClass A Common StockSEC:0001628280-26-052031:1
2,500 shares@ US$1.010.0005% mcap1.9% of flowClass A Common StockSEC:0001628280-26-047710:0
2,500 shares@ US$16.000.0084% mcap30.0% of flowClass A Common StockSEC:0001628280-26-047710:1
7,500 sharesClass A Common StockSEC:0001628280-26-046653:0
10,000 shares@ US$16.00854.6% of flowClass A Common StockSEC:0001628280-26-046653:2
2,500 sharesClass A Common StockSEC:0001628280-26-046653:1
4,400 shares@ US$1.260.0011% mcap4.0% of flowClass A Common StockSEC:0001437749-26-005892:0
400 shares@ US$1.260.4% of flowClass A Common StockSEC:0001437749-26-004126:0
1,250 shares@ US$3.68100.0% of flowCommon StockSEC:0001372514-24-000115:0
Canonical exit: 10 Dec 2024 (T+90)
12 of 12 declarations
